{"url_path":"/sec/vstm/8-k/2026-06-23/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1526119/0001104659-26-076809-index.html","accession_number":"0001104659-26-076809","cik":"0001526119","ticker":"VSTM","issuer_name":"Verastem, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1526119/0001104659-26-076809-index.html","primary_entity_key":"0001526119","primary_entity_name":"Verastem, Inc."},"word_count":94,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure.**\n\n \n\nOn June 23, 2026, Verastem,\nInc. (the “Company” or “Verastem”) posted a presentation to its website, which the Company intends to use during\nits previously announced investor conference call and webcast to review the preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical\ntrial evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, in patients with advanced KRAS G12D-mutated solid tumors,\non June 23, 2026, at 4:30 p.m. Eastern Time. A copy of the presentation is furnished hereto as Exhibit 99.1 to this Current Report on\nForm 8-K."}